HCC: ‘landmark’ immunotherapy combination listed on PBS

The PBS listings for atezolizumab (Tecentriq) and bevacizumab (Avastin) have been expanded to allow use in combination to treat patients with advanced unresectable hepatocellular carcinoma. From 1 November, more than 500 patients a year will be able to access the combination of a PD-L1 immunotherapy and anti-VEGF therapy for the treatment of unresectable locally advanced ...

Already a member?

Login to keep reading.

© 2021 the limbic